New obesity drug MBX 4291 enters first human safety trial
NCT ID NCT07142707
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times
Summary
This early-stage study tests a new drug called MBX 4291 in 124 adults with obesity (BMI 30 to under 50). The main goal is to see if the drug is safe and how well people tolerate it. Participants receive either the drug or a placebo as an injection under the skin. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MBX Biosciences Investigational Site
RECRUITINGLexington, Kentucky, 40509, United States
-
MBX Biosciences Investigational Site
RECRUITINGKnoxville, Tennessee, 37920, United States
Conditions
Explore the condition pages connected to this study.